Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 184Carcinoma, Non-Small-Cell Lung 142Multiple Myeloma 119Prostatic Neoplasms 116Colorectal Neoplasms 75Leukemia, Myeloid, Acute 74Neoplasms 73Melanoma 71Squamous Cell Carcinoma of Head and Neck 65Lymphoma 64Lung Neoplasms 64Neoplasm Metastasis 63Pancreatic Neoplasms 55Ovarian Neoplasms 49Sarcoma 45Carcinoma, Renal Cell 45Triple Negative Breast Neoplasms 42Urinary Bladder Neoplasms 41Leukemia, Lymphocytic, Chronic, B-Cell 41Glioblastoma 41Carcinoma, Hepatocellular 41Recurrence 40Head and Neck Neoplasms 37Lymphoma, Large B-Cell, Diffuse 35Brain Neoplasms 35Myelodysplastic Syndromes 34Hematologic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Lymphoma, Non-Hodgkin 33Lymphoma, Mantle-Cell 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × HR+/HER2- Breast Cancer × Clear all
NCT07130643 2025-08-19

Efficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer

Hubei Cancer Hospital

Phase 2 Active not recruiting
40 enrolled
Breast

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡